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Everybody would agree in saying that 
advances in Medicine, in the last decades, 
have lead to significant increase in life 
expectancy. However, the direct impact of 
global drug development might be harder 
to be precisely defined. Let then consider the 
following example. In the years between 1990 
and 1994 AIDS was the first cause of death 
among people <45 in USA, with up to 40 
deaths/year/100,000. In 1996–1998, AIDS-
related deaths dropped sharply, far below 
cancer and cardiovascular deaths, down to 
10/year/100,000, as a result of approval by 
FDA of novel drugs to treat HIV infection, 
such as protease inhibitors. Here a striking 
example of the impact of drug discovery on 
life expectancy. But where did these novel 
drugs come from? At variance with reverse 
transcriptase inhibitors, the discovery of 
first HIV protease inhibitors did not come 
from massive screening of randomly gen-
erated chemical libraries, but rather from 
a rational process, based on detailed study 
of proteolytic mechanisms in vertebrates 
and in HIV, analysis of differences in these 
processes, drug design based on transition 
state mimetic concept, an approach that had 
already been successfully used in the design 
of inhibitors of other aspartic proteinases 
such as renin (Roberts et al., 1990). This 
example tells us two important things: (1) 
drug discovery may rapidly and dramati-
cally change every day life; (2) innovative 
drugs may be obtained through rational, 
analytical research.
What do We mean by “analytical 
and experimental” 
pharmacology?
We may propose that it is the analytical 
study of the mechanism of drug action, at 
the molecular, cellular and organism lev-
els. This involves in silico analysis, quan-
titative structure–activity relationship 
(QSAR), drug design, as well as investiga-
tion on experimental drugs (compounds 
acknowledged as useful research tools, but 
not intended for human use) or  further 
 investigation on drugs approved and 
already in use. Conceptually, the first, lower 
level of analysis is the molecular one, which 
is the interaction of the drug with biomo-
lecular targets such as, in many instances, 
receptors. This seems obvious to us, but 
certainly was not obvious in the 50s, when, 
for example, the study of pharmacology of 
catecholamines was moving its first steps. 
At that time, very few people in the world 
were using the term “receptor” and none of 
them had any idea about the physical entity 
they were dealing with (a transmembrane 
protein, product of gene expression). The 
most strenuous defender and propagator 
of that concept, Ahlquist, thought, in fact, 
that receptor was an idea, useful to explain 
the physiological effects of adrenaline 
and isoprenaline on cardiovascular and 
respiratory systems, rather than a physi-
cal object interacting with hormones and 
drugs (Ahlquist, 1973). Nevertheless, this 
way of thinking (and acting) about recep-
tors, affinity, efficacy, agonists, antagonists, 
etc… produced the paradigm that founded 
the modern pharmacology and impressed 
a robust momentum to drug discovery and 
development of pharmaceutical industry. 
In this pioneering time, the technology 
available to any potential pharmacolo-
gist was minimal; no commercial fine 
chemistry, no commercial machines, no 
computers, very limited funding either 
governmental/no-profit or private/cor-
porate. Drug discovery often moved from 
serendipitous observations or, less often, 
from existing endogenous biomolecules, 
used as lead compounds for synthesizing 
new drugs, as, for example, Black et al. 
(1965) did for beta-blockers. The avail-
ability of these new selective agents further 
drove the research to understand recep-
tor distribution, subtypes, physiological 
effects related to their stimulation. At that 
time the analysis of interaction between 
drug and receptor was conducted at the 
organism level (blood pressure, heart 
rate, glucose, and electrolytes in blood 
and urine) or at the organ level (isolated 
 vessels, isolated whole heart/Langendorf, 
isolated papillary muscle, isolated bron-
chi). The pharmacological analysis barely 
involved the cell level. In the 70s, commer-
cial availability of devices for measuring 
beta and gamma emission together with 
commercial availability of radioisotopes 
and/or radioligands (drugs bearing radio-
active isotopes in their molecule) permit-
ted systematic and quantitative studies of 
drug receptor binding, demonstrating the 
physical existence of receptors as discrete 
entities, showing their precise distribution, 
measuring their abundance and affinity. 
Until this time, the analysis of drug effects 
was still carried out at the organism/organ 
level. The goals of drug discovery (and of 
Pharmacology) were therefore focused on 
obtaining tools for changing physiologi-
cal parameters which would possibly posi-
tively influence the disease outcome and/
or relieve/palliate some symptoms. Very 
little was known about the fundamental 
mechanisms of major human chronic dis-
eases (cardiovascular, diabetes, cancer), the 
cellular and the molecular level of analy-
sis remained off limits for Pharmacology. 
The goal of developing and implementing 
anti-infectious agents (antibiotics), since 
the 40s, and anticancer drugs, since the 60s, 
oriented pharmacological research toward 
the cellular and the molecular levels. The 
major parameter of drug efficacy consid-
ered in this context was cell proliferation, 
but relevant was also the analysis of meta-
bolic bacterial pathways at the biochemical 
level. In the meanwhile, electrophysiology 
was bursting neuroscience, demonstrating 
the electrical/chemical coupling in central 
and peripheral nervous system, i.e., the 
effect of neurotransmitters (and/or their 
synthetic counterparts, agonists and antag-
onists) at the cellular level (action poten-
tial, IPSP, and EPSP) in the 60s (Eccles 
and Liley, 1959; Eccles et al., 1963), and 
at the molecular level (i.e., single channel 
record) in the 70s (Neher and Sakmann, 
Frontiers in Pharmacology | Experimental Pharmacology and Drugs Discovery September 2010 | Volume 1 | Article 119 | 2
Salomone Challenges in analytical pharmacology
validation of drug efficacy, therefore starts 
flowing from technologies that allow large, 
comprehensive screening of information 
carried by biomolecules. This ambition 
is summarized in the –ome paradigm: 
genome, transcriptome, proteome, indi-
cate complete sets of categories (genes, 
transcripts, proteins) accessible to direct 
scrutiny. Gene expression profiling meas-
ures the expression level of thousands of 
genes at once, creating a global picture of 
cell function. These profiles enable one to 
distinguish, for example, between normal 
differentiated quiescent cells in a control 
sample from those transformed in a tumor 
specimen; furthermore, gene expression 
profiling may show if cancer cells respond 
to a particular drug treatment or develop 
drug resistance, by changing the expres-
sion of genes involved in apoptosis, cell 
cycle, etc… DNA Microarray technology 
measures the relative activity of previously 
identified target genes, whereas sequence 
based techniques, like serial analysis of 
gene expression (SAGE, SuperSAGE) 
can accurately measure any active gene, 
not just a predefined set. More recently, 
human genome-wide association studies 
deal with complex traits that consist of a 
limited number of common alleles, each 
conferring a small increase in risk to the 
individual. A substantial proportion of the 
human genome is comprised of regions that 
exhibit reduced recombination in human 
populations (haplotypes). Genetic variants 
within haplotypes are in linkage disequi-
librium. Several million single nucleotide 
polymorphisms (SNPs) have been identi-
fied and genome-wide maps of SNP are 
available. These resources, together with 
platforms for massive SNP genotyping, 
have rendered genome-wide association 
studies feasible for diseases such as diabetes 
mellitus (Saxena et al., 2007), myocardial 
infarction (Mizuno et al., 2006), cancer 
(Gudmundsson et al., 2007), inflamma-
tory bowel disease (Xavier and Podolsky, 
2007).
Other techniques, like the two-hybrid 
screening (also known as yeast two-hybrid 
system or Y2H), allow massive analysis of 
protein–protein interactions or protein–
DNA interactions (for DNA-binding pro-
teins, such as transcription factors). These 
technologies have lead to the constructions 
of interactomes, i.e., maps of all the protein–
structure rigidity, the two most important 
features distinguishing approved drugs 
and natural products from randomly 
synthesized combinatorial compounds. 
High-throughput screening (HTS) is the 
method that allows a researcher to conduct 
as many as millions of biological tests. HTS 
uses automation to screen libraries of can-
didate compounds against targets, looking 
for specific activity such as inhibition or 
stimulation of defined biological mecha-
nisms. Microtiter plates, filled with nano-
liters of solution containing the reactants, 
are incubated and then read by automated 
analysis machines. Current HTS robots can 
test up to 100,000 compounds per day, but 
higher performance systems are also avail-
able. Recently, an HTS process that uses 
drop-based microfluidics, allowing 100 
million reactions in 10 h, has been reported 
(Agresti et al., 2010).
Back in the 80s, it became clear that deci-
phering the entire genome of organisms 
was possible and that sequencing human 
genome, for example, was a valuable task 
deserving significant resources. This view 
lead to complete sequencing of human 
genome in 2000. Increasing availability 
of information and technology made the 
new paradigm applicable to all fields of 
life science, including those with practical 
significance for every day needs, such as 
medicine and agriculture. The enormous 
and continuously growing amount of data 
generated in the last 20 years, by system-
atic study of the molecular mechanisms in 
cardiovascular diseases, diabetes, cancer, 
permitted an understand of the molecular 
basis of diseases. The goals of drug discov-
ery and pharmacology become therefore 
focused on obtaining tools for modifying 
specific molecular targets, possibly leading 
to definitive cure of the disease. Sometimes, 
it is possible to make specific prediction 
about levels of gene expression in disease; 
but more commonly, expression profiling 
takes place before enough is known about 
how genes interact with experimental con-
ditions for a testable hypothesis to exist. In 
some of these cases, expression profiling 
helps to identify candidate genes relevant 
for mechanisms of disease and/or novel 
potential drug targets. Molecular analysis 
at the concept level (molecular mechanism 
of the disease, potential drug target), fol-
lowed by drug design and experimental 
1976). The true paradigm shift in life sci-
ences, however, occurred in the 80s, when 
rapid advances in molecular biology pro-
duced novel knowledge and novel technol-
ogy that spread all around the world. This 
shift was founding an ultimate ambitious 
reductionism, still prevalent in now days, 
stating that all kind of life may be under-
stood (and manipulated) as information 
encoded in biomolecules (DNA, RNA, 
proteins). The analysis of mechanisms 
of drug action therefore has definitively 
advanced to the molecular level. The para-
digm shift represented by the biomolecular 
reductionism, has also changed the path to 
drug discovery, and its impact in every-day 
drug therapy is continuously and rapidly 
growing.
random screening and concept-
driven screening
In its beginnings, drug discovery was slowly 
progressing, based mainly on tradition and 
serendipity, i.e., systematic pharmacologi-
cal analysis of traditional remedies or for-
tuitous discovery of new effects. In few 
cases, when concept-driven, the discovery 
of new drugs was guided by analysis of 
“endogenous leads” (as mentioned above 
for beta-blockers). More recently, since 
the 70s, drug discovery had moved from 
the analysis of a known target (a recep-
tor) to the random screening of numerous 
candidate compounds potentially binding 
the target (agonist, antagonists, etc…) and 
thereby modifying a given physiological 
function. Combinatorial chemistry pro-
vides, by random synthesis, large sets of 
compounds (libraries). Robotics enable 
routinely production of over 100,000 new 
and unique compounds per year. In order 
to handle the vast number of structural 
possibilities, researchers often create in 
silico libraries, consisting of thousands to 
millions of “virtual” compounds; selected 
subsets of the “virtual library” may even-
tually undergo actual synthesis, based 
upon further analysis (pharmacokinetics, 
computational chemistry, and QSAR). 
Although combinatorial chemistry has 
been an essential part of drug discovery, 
a large proportion of new chemical enti-
ties still are nature-derived compound. As 
Feher and Schmidt (2003) pointed out, 
this may be in part related to the fact that 
combinatorial libraries lack chirality and 
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Organism analysis is essential for dem-
onstrating the drug effect(s) that are exploit-
able to cure diseases or relieve symptoms. 
In most instances this cannot be deduced 
solely by analysis at the molecular and/
or cellular level, because the mechanism 
of the disease (and of the cure) operate 
exclusively at the organism level. Here few 
examples: diseases like migraine, epilepsy, 
brain ischemia, asthma, heart failure, liver 
cirrhosis; symptoms like tremor, amnesia, 
hypertension, vomits, fever, diarrhea.
These three fundamental levels of analy-
sis today are not dispensable when devel-
oping new therapeutics, but can also be 
applied to already existing and approved 
drugs, to unravel novel indications and/or 
to predict potential harmful effects.
Finally, a further, more recently intro-
duced, fourth level of analysis is that of indi-
vidualized pharmacology, i.e., the analysis 
of the effect of genetic variation on drug 
response in patients, by correlating gene 
expression level and/or SNPs with drug effi-
cacy or toxicity. The challenge introduced 
by pharmacogenomic analysis is to optimize 
drug therapy for each individual’s unique 
genetic makeup, ensuring maximum effi-
cacy while minimizing adverse effects.
(or excluding) off target effects, but also 
for understanding complex in vivo effects, 
resulting from modification of expression 
of multiple genes. Different issues may 
apply to aptamers, DNA- or RNA-related 
compounds that exert biological actions 
not through the information encoded in 
their sequence, but by specifically interact-
ing with biomolecules (somehow like the 
classical chemically synthesized drugs). The 
mechanism of action of these agents might 
still be analyzed in terms of QSAR, affinity, 
efficacy. This field is likely to substantially 
grow in the next years, because patents 
restricting the diffusion of the aptamer-
related technology are expiring. Specific 
issues, however, may concern the pharma-
cokinetics of aptamers, their molecular size 
being usually bigger than classical, chemi-
cally synthesized, drugs.
What kind of pharmacological 
analysis do We need today?
Molecular analysis is essential in drug 
design and discovery; this is mostly carried 
out on lead compounds, either derived from 
random HTS or from concept-driven iden-
tification of molecular target (gene profiling 
analysis followed by in silico QSAR and drug 
synthesis).
Cellular analysis is essential for assess-
ing the consequences of drug–target 
interaction on cell physiology and sign-
aling (generation of second messengers, 
calcium release from endoplasmic reticu-
lum, calcium waves and spikes, electrical 
protein or protein–DNA interactions in dif-
ferent species, including human. Analysis of 
interactomes are increasingly proven useful 
in studying signaling pathways downstream 
receptor activation, including kinases 
involved in receptor phosphorylation and 
down-regulation.
analytical pharmacology for 
drugs of 21st century
A significant proportion of newly approved 
drugs (over 25%) is now days represented 
by biologicals (or biotechnology-derived 
pharmaceuticals); many of them are mono-
clonal antibodies, often intended for cancer 
treatment, other are DNA and RNA species 
(including siRNA), intended for acting in a 
sequence-specific manner (i.e., the Watson 
and Crick base pairing is exploited to obtain 
drug-specificity). For these new drug types 
new categories of analysis are required. The 
regulatory agencies are setting specific 
rules for approval, though most of the 
classical preclinical pharmacological and 
toxicological analysis remain mandatory. 
Biological activity may be evaluated using 
in vitro assays, including cell lines and/or 
primary cell cultures to examine the direct 
effects on cellular phenotype and prolifera-
tion; in vitro studies are also designed to 
determine receptor occupancy and recep-
tor affinity. Due to the species specificity of 
many biologicals, it is important to select 
relevant animal species for in vivo test-
ing. Large gene expression profiling may 
become essential not only for showing 
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